Search Results

PharmEnable Therapeutics, a UK drug discovery company, and Sosei Heptares (TSE: 4565), the international biopharmaceutical company

Sosei Group Corporation (“Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD).

Sosei Group Corporation, will hold an investor and press conference on ’s announcement; “Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC, Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company.”

Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2023 on Tuesday, 13 February 2024.

Sosei Group Corporation and Cancer Research UK announce that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ orally available small molecule cancer immunotherapy drug HTL0039732 for advanced solid tumors.

Sosei Group Corporation announces that Formosa Pharmaceuticals, Inc. has received approval from the US Food & Drug Administration for clobetasol propionate ophthalmic suspension 0.05%, for the treatment of post-operative inflammation and pain following ocular surgery.

Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Sosei Group Corporation announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held in Tokyo.

Boehringer Ingelheim and Sosei Group Corporation announced they have entered a global collaboration and exclusive option-to-license agreement.

Sosei Group Corporation, announces its President & CEO, Chris Cargill, will present at the 42nd Annual J.P. Morgan Healthcare Conference.